Publications
165 results found
Howell J, Atkinson SR, Pinato DJ, et al., 2018, Identification of mutations in circulating cell-free tumor DNA as a prognostic biomarker in hepatocellular carcinoma, Publisher: WILEY, Pages: 29-29, ISSN: 0815-9319
Shabeer LL, Khan SA, 2018, MEDICAL STUDENTS' PERCEPTION OF UNDERGRADUATE HEPATOLOGY TEACHING IN THE UK - A NATIONAL SURVEY, Annual General Meeting of the British-Society-of-Gastroenterology, Publisher: BMJ PUBLISHING GROUP, Pages: A278-A278, ISSN: 0017-5749
Rizvi S, Khan SA, Hallemeier CL, et al., 2018, Cholangiocarcinoma - evolving concepts and therapeutic strategies, NATURE REVIEWS CLINICAL ONCOLOGY, Vol: 15, Pages: 95-111, ISSN: 1759-4774
- Author Web Link
- Cite
- Citations: 863
Forlano R, Manousou P, Mullish BH, et al., 2017, Assessment of non invasive markers of fibrosis against collagen quantitation and NASH-CRN scoring in liver biopsies of NAFLD patients, The AASLD Liver Meeting 2017, Publisher: Wiley, Pages: 334A-334A, ISSN: 0270-9139
Mullish BH, Forlano R, Yee M, et al., 2017, Development of an algorithm for the prediction of cardiovascular events in patients with NAFLD: the role of mean platelet volume, The AASLD Liver Meeting 2017, Publisher: Wiley, Pages: 1175A-1176A, ISSN: 0270-9139
Kumar N, Khamri W, Sadiq F, et al., 2017, Circulating Natural Killer cells in Hepatocellular Carcinoma are hypofunctional with an exhausted phenotype, 68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Publisher: WILEY, Pages: 355A-355A, ISSN: 0270-9139
Sheridan DA, Aithal G, Alazawi W, et al., 2017, Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey, FRONTLINE GASTROENTEROLOGY, Vol: 8, Pages: 252-+, ISSN: 2041-4137
- Author Web Link
- Cite
- Citations: 18
Hughes T, O'Connor T, Namwat N, et al., 2017, Opisthorchiasis and cholangiocarcinoma in South East Asia: an unresolved problem, International Journal of General Medicine, Vol: 2017, Pages: 227-237, ISSN: 1178-7074
The prevalence of cholangiocarcinoma (CCA) in Southeast Asia is much higher than other areas of the world. Eating raw, fermented or undercooked cyprinid fish, infected with the liver fluke, Opisthorchis viverrini sensu lato, results in chronic biliary inflammation, periductal fibrosis, and increased cancer risk. There may be associated glomerulonephritis. The process of infection is difficult to disrupt because eating practices have proven extremely difficult to change, and the life cycle of the fluke cannot be broken due to high prevalence in canine and feline reservoir hosts. Fecal analysis and ELISA tests can be used to diagnose opisthorchiasis. Diagnosis of CCA is complex, partly due to the lack of definitive imaging characteristics and also due to the difficulty of obtaining samples for cytology or histology. This cancer has proven to be resistant to common chemotherapy treatments and so the two avenues of treatment available are surgical resection and liver transplantation, both requiring early detection of the tumor for the best chances of success. Late presentation of symptoms reduces the chances of successful surgical intervention. While liver fluke infections can be treated with praziquantel, individuals will often become re-infected, and multiple reinfections can be more harmful than a singular, long term infection. A key research need is for the detection and characterization of novel biomarkers in all parts of the carcinogenic pathway for early diagnosis.
Carruthers J, Bottle R, Laverty AA, et al., 2017, Nation-wide trends in non-alcoholic steatohepatitis (NASH) in patients with and without diabetes between 2004-05 and 2014-15 in England, Diabetes Research and Clinical Practice, Vol: 132, Pages: 102-107, ISSN: 1872-8227
AimsThere are no national studies evaluating the epidemiology of non-alcoholic steatohepatitis (NASH) in England. NASH is becoming an increasingly important health issue given the inexorable rise in obesity and diabetes. We evaluated the rates of NASH in people with and without diabetes from 2004–2005 to 2014–2015.MethodsWe identified cases of biopsy-proven NASH in people with and without diabetes in England over an eleven-year period using Hospital Episode Statistics. We estimated incidence rates for each year. Negative binomial regression models were fitted to test trends.ResultsOver the study period, people without diabetes recorded a 3% reduction in admission rates per year (incidence rate ratio (IRR) (95% CI) 0.97 (0.96–0.98), p < 0.001), whilst there was an increase in admission rates in people with diabetes (IRR (95% CI) 1.01 (1.00–1.02), p = 0.04). In people with diabetes, this upward trend was driven by people over 65 years (IRR (95% CI) 1.03 (1.02–1.04), p < 0.001) and men (IRR (95% CI) 1.01 (1.0–1.02), p = 0.03). Inpatient mortality declined for people with diabetes by 2% per year after adjusting for age, sex and year (IRR (95% CI) 0.98 (0.95–0.99), p = 0.03). The 2% decline per year in inpatient mortality for people without diabetes did not achieve statistical significance after adjustment (IRR (95% CI) 0.98 (0.95–1.01), p = 0.175).ConclusionsThere was a decline in NASH-related hospital admissions amongst people without diabetes over eleven years, whilst rates increased in people with diabetes. These observations highlight the increasing burden of NASH.
Mullish BH, Forlano R, Yee M, et al., 2017, Development Of An Algorithm For The Prediction Of Cardiovascular Events In Patients With NAFLD: The Role Of Mean Platelet Volume., BASL 2017 Annual Meeting
Khan SA, McClements S, Reccia I, et al., 2017, The next generation of hepatocellular cancer experts: what do they think?, Hepatic Oncology, Vol: 3, Pages: 213-215, ISSN: 2045-0923
Forlano R, Mullish BH, Angkathunyakul N, et al., 2017, PWE-094 The severity of steatosis does not influence liver stiffness measurements in patients with non-alcoholic fatty liver disease, British Society of Gastroenterology Annual Meeting, Publisher: BMJ Publishing Group, Pages: A174-A174, ISSN: 1468-3288
Forlano R, Maurice J, Mullish BH, et al., 2017, The severity of steatosis does not influence liver stiffness measurements in patients with Non-Alcoholic Fatty Liver Disease, International Liver Conference, Publisher: Elsevier, Pages: S586-S587, ISSN: 0169-5185
Carruthers J, Bottle R, Laverty AA, et al., 2017, Nationwide trends in non-alcoholic steatohepatitis in patients with and without diabetes between 2004 and 2014 in England, Diabetes UK Annual Professional Conference, Publisher: Wiley, Pages: 67-67, ISSN: 1464-5491
Howell J, Atkinson S, PInato DJ, et al., 2017, Identification of actionable mutations in circulating cell-free tumour DNA as a prognostic biomarker in hepatocellular carcinoma, International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Publisher: ELSEVIER SCIENCE BV, Pages: S449-S449, ISSN: 0168-8278
Howell JA, Khan SA, Knapp S, et al., 2016, The clinical role of circulating free tumor DNA in gastrointestinal malignancy, Translational Research, Vol: 183, Pages: 137-154, ISSN: 1931-5244
Circulating cell-free DNA (cfDNA) is DNA released from necrotic or apoptotic cells into the bloodstream. While both healthy cells and cancer cells release cfDNA, tumors are associated with higher levels of tumor-derived circulating cell-free DNA (ctDNA) detectable in blood. Absolute levels of ctDNA and its genetic mutations and epigenetic changes show promise as potentially useful biomarkers of tumor biology, progression, and response to therapy. Moreover, studies have demonstrated the discriminative accuracy of ctDNA levels for diagnosis of gastrointestinal cancer compared with benign inflammatory diseases. Therefore, ctDNA detected in blood offers a minimally invasive and easily repeated "liquid biopsy" of cancer, facilitating real-time dynamic analysis of tumor behavior that could revolutionize both clinical and research practices in oncology. In this review, we provide a critical summary of the evidence for the utility of ctDNA as a diagnostic and prognostic biomarker in gastrointestinal malignancies.
Valle JW, Borbath I, Khan SA, et al., 2016, Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, ANNALS OF ONCOLOGY, Vol: 27, Pages: v28-v37, ISSN: 0923-7534
- Author Web Link
- Cite
- Citations: 417
Liu NJ, Chapman R, Lin Y, et al., 2016, Phospholipase A2 as a point of care alternative to serum amylase and pancreatic lipase, Nanoscale, Vol: 8, Pages: 11834-11839, ISSN: 2040-3372
Acute pancreatitis is a relatively common and potentially fatal condition, but the presenting symptoms are non-specific and diagnosis relies largely on the measurement of amylase activity by the hospital clinical laboratory. In this work we develop a point of care test for pancreatitis measuring concentration of secretory phospholipase A2 group IB (sPLA2-IB). Novel antibodies for sPLA2-IB were raised and used to design an ELISA and a lateral flow device (LFD) for the point of care measurement of sPLA2-IB concentration, which was compared to pancreatic amylase activity, lipase activity, and sPLA2-IB activity in 153 serum samples. 98 of these samples were obtained from the pathology unit of a major hospital and classified retrospectively according to presence or absence of pancreatitis, and the remaining 55 were obtained from commercial sources to serve as high lipase (n = 20), CA19-9 positive (n = 15), and healthy (n = 20) controls. sPLA2-IB concentration correlated well with the serum activity of both amylase and lipase, and performed at least as well as either markers in the differentiation of pancreatitis from controls.
Pinato DJ, Stebbing J, Ishizuka M, et al., 2016, Corrigendum to “A novel and validated prognostic index in hepatocellular carcinoma: The Inflammation Based Index (IBI)”, Journal of Hepatology, Vol: 65, Pages: 453-453, ISSN: 1600-0641
Phillips N, Tyreman M, Bentham A, et al., 2016, NOVEL POINT OF CARE TEST FOR DETECTION OF HUMAN PHOSPHOLIPASE A2 TO PREDICT ACUTE PANCREATITIS POST ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY (ERCP) AND AID SAME DAY DISCHARGE, GUT, Vol: 65, Pages: A44-A45, ISSN: 0017-5749
Howell JA, Khan SA, 2016, The role of miRNAs in cholangiocarcinoma, HEPATIC ONCOLOGY, Vol: 3, Pages: 167-180, ISSN: 2045-0923
- Author Web Link
- Cite
- Citations: 4
Cross TJS, Villanueva A, Shetty S, et al., 2016, A national survey of the provision of ultrasound surveillance for the detection of hepatocellular carcinoma., Frontline Gastroenterol, Vol: 7, Pages: 82-89, ISSN: 2041-4137
OBJECTIVE: Hepatocellular carcinoma (HCC), the sixth most common cancer worldwide and third most common cause of cancer related death, is closely associated with the presence of cirrhosis. Survival is determined by the stage of the cancer, with asymptomatic small tumours being more amenable to treatment. Early diagnosis is dependent on regular surveillance and the primary objective of this survey was to gain a better understanding of the baseline attitudes towards and provision of ultrasound surveillance (USS) HCC surveillance in the UK. In addition, information was obtained on the stages of cancer of the patients being referred to and discussed at regional multidisciplinary team meetings. DESIGN: UK hepatologists, gastroenterologists and nurse specialists were sent a questionnaire survey regarding the provision of USS for detection of HCC in their respective hospitals. RESULTS: Provision of surveillance was poor overall, with many hospitals lacking the necessary mechanisms to make abnormal results, if detected, known to referring clinicians. There was also a lack of standard data collection and in many hospitals basic information on the number of patients with cirrhosis and how many were developing HCC was not known. For the majority of new HCC cases was currently being made only at an incurable late stage (60%). CONCLUSIONS: In the UK, the current provision of USS based HCC surveillance is poor and needs to be upgraded urgently.
Moghul I, Appleby RN, Khan S, et al., 2016, Bile Acid Diarrhea and Low Fibroblast Growth Factor 19 (FGF19) Are Associated With Non-Alcoholic Fatty Liver Disease (NAFLD) and Metformin Use, Digestive Disease Week (DDW), Publisher: W B SAUNDERS CO-ELSEVIER INC, Pages: S125-S126, ISSN: 0016-5085
Moghul I, Appleby RN, Khan S, et al., 2016, Diarrhea and High 7-Hydroxy-4-Cholesten-3-One (C4), But Not Low Fibroblast Growth Factor 19 (FGF19) Are Predictors of High Non-Alcoholic Fatty Liver Disease (NAFLD) Fibrosis Score, 57th Annual Meeting and Residents Fellow Conference of the Society-for-Surgery-of-the-Alimentary-Tract (SSAT) / 52nd Annual Meeting on Digestive Disease Week (DDW) / Meeting of the American-Gastroenterological-Association (AGA), Publisher: W B SAUNDERS CO-ELSEVIER INC, Pages: S717-S717, ISSN: 0016-5085
Adler M, Manousou P, Rishi I, et al., 2016, ELEVATED MEAN PLATELET VOLUME IMPROVES CURRENT NON-INVASIVE MARKERS OF FIBROSIS AND PREDICTS ACUTE CARDIOVASCULAR EVENTS IN NON-ALCOHOLIC FATTY LIVER DISEASE PATIENTS, EASL International Liver Congress, Publisher: ELSEVIER SCIENCE BV, Pages: S494-S495, ISSN: 0168-8278
Shariff MIF, Tognarelli JM, Lewis MR, et al., 2015, Plasma Lipid Profiling in a Rat Model of Hepatocellular Carcinoma: Potential Modulation Through Quinolone Administration, JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, Vol: 5, Pages: 286-294, ISSN: 0973-6883
- Author Web Link
- Cite
- Citations: 6
Nooredinvand HA, Connell DW, Asgheddi M, et al., 2015, Viral hepatitis prevalence in patients with active and latent tuberculosis, World Journal of Gastroenterology, Vol: 21, Pages: 8920-8926, ISSN: 1007-9327
AIM: To assess the prevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection and association with drug induced liver injury (DILI) in patients undergoing anti-tuberculosis (TB) therapy.METHODS: Four hundred and twenty nine patients with newly diagnosed TB - either active disease or latent infection - who were due to commence anti-TB therapy between September 2008 and May 2011 were included. These patients were prospectively tested for serological markers of HBV, HCV and human immunodeficiency virus (HIV) infections - hepatitis B core antigen (HBcAg), hepatitis B surface antigen (HBsAg), hepatitis B e antigen, IgG and IgM antibody to HBcAg (anti-HBc), HCV IgG antibody and HIV antibody using a combination of enzyme-linked immunosorbent assay, Western blot assay and polymerase chain reaction techniques. Patients were reviewed at least monthly during the TB treatment initiation phase. Liver function tests were measured prior to commencement of anti-TB therapy and 2-4 wk later. Liver function tests were also performed at any time the patient had significant nausea, vomiting, rash, or felt non-specifically unwell. Fisher’s exact test was used to measure significance in comparisons of proportions between groups. A P value of less than 0.05 was considered statistically significant.RESULTS: Of the 429 patients, 270 (62.9%) had active TB disease and 159 (37.1%) had latent TB infection. 61 (14.2%) patients had isolated anti-HBc positivity, 11 (2.6%) were also HBsAg positive and 7 (1.6%) were HCV-antibody positive. 16/270 patients with active TB disease compared to 2/159 patients with latent TB infection had markers of chronic viral hepatitis (HBsAg or HCV antibody positive; P = 0.023). Similarly the proportion of HBsAg positive patients were significantly greater in the active vs latent TB infection group (10/43 vs 1/29, P = 0.04). The prevalence of chronic HBV or HCV was significantly higher than the estimated United Kingdom prevalence of 0.3% for each
Khan SA, 2015, The changing etiology of liver cancer, HEPATIC ONCOLOGY, Vol: 2, Pages: 221-223, ISSN: 2045-0923
Taylor-Robinson SD, Wong J, Crossey MME, et al., 2015, Evidence is weak to support hepatocellular carcinoma screening in chronic liver disease., Evid Based Med, Vol: 20
Chapman R, Lin Y, Burnapp M, et al., 2015, Multivalent nanoparticle networks enable point-of-care detection of human phospholipase-A2 in serum, ACS Nano, Vol: 9, Pages: 2565-2573, ISSN: 1936-086X
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.